To include your compound in the COVID-19 Resource Center, submit it here.

Drug platforms

TECHNOLOGY: Cell therapy

An IL-2/CD122-based signaling system could help increase the efficacy of T cell therapies for cancer without the toxicity of wild-type

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE